Cargando…

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection

Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation. PI3K catalytic p110 subunits are divided into 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pillinger, Genevra, Loughran, Niamh V., Piddock, Rachel E., Shafat, Manar S., Zaitseva, Lyubov, Abdul-Aziz, Amina, Lawes, Matthew J., Bowles, Kristian M., Rushworth, Stuart A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129970/ https://www.ncbi.nlm.nih.gov/pubmed/27174919 http://dx.doi.org/10.18632/oncotarget.9289

Ejemplares similares

PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment
por: Piddock, R E, et al.
Publicado: (2017)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
por: Pillinger, Genevra, et al.
Publicado: (2015)

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML
por: Zaitseva, Lyubov, et al.
Publicado: (2014)

The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma
por: Piddock, Rachel E., et al.
Publicado: (2017)

Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ
por: Uehara, Mayuko, et al.
Publicado: (2017)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYC
por: Piddock, Rachel E., et al.
Publicado: (2018)

Hyper-activated PI3K-δ in immunodeficiency
por: Heurtier, Lucie, et al.
Publicado: (2015)

The Treatment of Activated PI3Kδ Syndrome
por: Coulter, Tanya I., et al.
Publicado: (2018)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
por: Rao, V. Koneti, et al.
Publicado: (2023)

PI3Kδ is indispensable for CTL-mediated cytotoxicity
por: Putz, Eva M, et al.
Publicado: (2011)

Coordinate PI3K pathway and Bcl-2 family disruption in AML
por: Bose, Prithviraj, et al.
Publicado: (2012)

PI3Kδ过度活化综合征一例
Publicado: (2021)

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
por: Darici, Salihanur, et al.
Publicado: (2020)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
por: Liu, Xiaochuan, et al.
Publicado: (2016)

PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma
por: Pongas, Georgios N., et al.
Publicado: (2017)

Roles of PI3K pan-inhibitors and PI3K-δ inhibitors in allergic lung inflammation: a systematic review and meta-analysis
por: Kim, Jong Seung, et al.
Publicado: (2020)

A Review of Phosphocreatine 3 Kinase δ Subtype (PI3Kδ) and Its Inhibitors in Malignancy
por: Xiang, Qiong, et al.
Publicado: (2021)

PI3Kδ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes
por: Putz, Eva Maria, et al.
Publicado: (2012)

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
por: Tarantelli, Chiara, et al.
Publicado: (2021)

Activated PI3Kδ syndrome – reviewing challenges in diagnosis and treatment
por: Vanselow, Sven, et al.
Publicado: (2023)

Selection Study for B+- -> (K-+ pi+- pi-+ pi+-)D K+- and B+- -> (K+ K- pi+ pi-)D K+-".
por: Hunt, P, et al.
Publicado: (2009)

$\pi \pi$ scattering lengths and $K \to 3\pi$ decays
por: Gallorini, Stefano
Publicado: (2013)

Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure
por: Jia, Wenqing, et al.
Publicado: (2022)

The investigation of $K^+\pi^−, \pi^+K^−$ and $\pi^+\pi^−$ atoms
por: Yazkov, Valeriy
Publicado: (2016)

Determination of the branching ratios $\Gamma(K_{L} \to 3\pi^{0}) / \Gamma(K_{L} \to \pi^{+}\pi^{-}\pi^{0})$ and $\Gamma(K_{L} \to 3\pi^{0}) / \Gamma(K_{L} \to \pi e\nu)$
por: Kreutz, A., et al.
Publicado: (1994)

Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
por: Lindblad, O, et al.
Publicado: (2016)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
por: Lauder, Sarah Nicol, et al.
Publicado: (2020)

Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach
por: Lauder, Sarah N., et al.
Publicado: (2021)

Targeting PI3Kδ: One man’s meat is another man’s poison
por: Prchal-Murphy, Michaela, et al.
Publicado: (2013)

Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients
por: Southworth, Thomas, et al.
Publicado: (2016)

Epidermodysplasia verruciformis in a young adult with activated PI3Kδ syndrome
por: Donaldson, Stephanie L., et al.
Publicado: (2019)

PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19
por: Palma, Giuseppe, et al.
Publicado: (2020)

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021)

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
por: Chandrasekaran, Sanjay, et al.
Publicado: (2021)

Study of the K+K-pi+pi- system centrally produced in the reactions pi+p --> pi+(K+K-pi+pi-)p and pp --> p(K+K-pi+pi-)p at 85 GeV/c
por: Armstrong, T A, et al.
Publicado: (1986)

Simultaneous production of K*0 (892) and Δ++(1236) in the reaction K+p→K+ $\pi^{+} \pi^{-}$ p from 4.3 to 5.0 GeV/c
por: Dehm, G, et al.
Publicado: (1974)

Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes
por: Redenbaugh, Vyanka, et al.
Publicado: (2021)

Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia
por: Wang, Xiang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_76k1atv9jcr2h7jhjvss92no8v